Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.
Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings)
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.72, a high estimate of $202.00, and a low estimate of $75.00. This current ...
Fintel on MSN10h
HC Wainwright & Co. Initiates Coverage of Kairos Pharma (KAPA) with Buy Recommendation
Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...
Kairos Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $12 price target The company’s oncology pipeline “could ...
SAB Biotherapeutics’ (SABS) Buy Rating Reaffirmed at HC Wainwright
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $6.
HC Wainwright Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...